证券代码：000028 、200028 证券简称：国药一致、一致 B 公告编号：2025-31 国药集团一致药业股份有限公司 关于 2024 年年度股东大会增加临时提案 暨股东大会补充通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国药集团一致药业股份有限公司（以下简称"公司"或"国药一致"）于 2025 年 4 月 8日披露了《关于召开公司 2024年年度股东大会的通知》（公 告编号：2025-24），公司将于 2025 年 6 月 10 日召开 2024 年年度股东大 会。 2025 年 5 月 28 日，公司召开第十届董事会 2025 年第六次临时会议， 审议通过了《关于修订<公司章程>及其附件的议案》及《关于增补第十届 董事会非独立董事的议案》。同日，公司董事会收到控股股东国药控股股 份有限公司（以下简称"国药控股"）提交的《关于增加 2024年年度股东大 会临时提案的函》，提议将上述议案以临时提案的方式提交至 2024 年年 度股东大会审议。 经核查，国药控股单独持有公司 311,999,988 股股份，占公司总股本 的56.06%，具备 ...

证券代码：000028 、200028 证券简称：国药一致、一致 B 公告编号：2025-29 国药集团一致药业股份有限公司 第十届董事会 2025 年第六次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"或"国药一致"） 第十届董 事会 2025 年第六次临时会议于 2025 年 5 月 23 日以电话和电子邮件方式发出通知和文 件材料，会议于 2025 年 5 月 28 日以通讯表决方式召开。应参加会议董事 7 名，亲自 出席会议董事 7 名。会议召开程序符合《公司法》、《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于修订<公司章程>及其附件的议案》 同意根据《中华人民共和国公司法》、中国证券监督管理委员会《上市公司章程 指引》等法律法规及规范性文件的规定并结合公司实际工作需要，对《公司章程》 《股东会议事规则》《董事会议事规则》作出相应修订，并废止《监事会议事规则》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。本议案需提交公司股东大会以特 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company, Guoyao Yizhi, reported a revenue of 18.29 billion yuan in Q1 2025, a year-on-year decrease of 4.2%, and a net profit attributable to shareholders of 330 million yuan, down 15.6% year-on-year [5] - The distribution segment's revenue in Q1 2025 was 13.59 billion yuan, a decline of 2.6% year-on-year, while the retail segment generated 4.98 billion yuan, down 7.5% year-on-year, but turned profitable compared to previous quarters [8] - The company is expected to see improvements in profitability throughout 2025, with projected net profits of 1.33 billion yuan, 1.50 billion yuan, and 1.67 billion yuan for 2025, 2026, and 2027 respectively, indicating growth rates of 107.1%, 12.5%, and 11.7% [8] Financial Summary - As of April 29, 2025, the company's closing price was 24.53 yuan, with a total market capitalization of 13.65 billion yuan and a circulating market capitalization of 13.48 billion yuan [3] - The company's total assets are projected to grow from 50.08 billion yuan in 2025E to 56.78 billion yuan in 2027E, while total liabilities are expected to increase from 28.07 billion yuan to 31.76 billion yuan over the same period [9] - The company's return on equity (ROE) is forecasted to improve from 3.64% in 2024 to 7.91% in 2027 [7]

Group 1: Industry Overview - The pharmaceutical distribution industry is transitioning from high growth driven by scale to slow growth focused on structural adjustments, influenced by policy changes, technological innovations, and market competition [3] - The industry exhibits weak cyclical characteristics due to rigid demand, maintaining relative stability despite challenges [3] - Policy adjustments, such as expanded centralized procurement, are impacting profit margins for distribution companies, while the demand for personalized services and smart supply chains is increasing [3] Group 2: Business Performance - The company maintains a leading market share in hospital direct sales, optimizing product and customer structure while controlling accounts receivable risks [4] - As of the end of 2024, the company has 162 specialty pharmacy stores in the Guangxi and Guangdong regions, with a 20% increase in SPD service fee revenue [4] - The retail segment (Guoda Pharmacy) has closed over 1,200 stores since 2024 to focus on high-quality development, with a total of 9,234 stores as of Q1 2025 [4] Group 3: Strategic Initiatives - The company is leveraging health management opportunities through policy changes, aiming to transform Guoda Pharmacy into a health management platform [5] - The company is focusing on improving gross margins through strategic adjustments, including optimizing product structure and enhancing self-owned brand sales [8] - AI technology is being integrated into standardized processes, although the industry still relies heavily on professional pharmacists for specialized tasks [8] Group 4: Future Outlook - The domestic pharmacy industry is expected to undergo consolidation, with approximately 700,000 pharmacies projected by 2024, exceeding market capacity [9] - The company anticipates continued growth in the DTP pharmacy market, driven by changes in reimbursement policies and the rapid introduction of new drugs [9] - The tightening of medical insurance qualifications is seen as a necessary evolution for the industry, promoting compliance and enhancing competitive strength [9]

国药集团一致药业股份有限公司 第十届监事会2025年第二次临时会议决议公告 证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-27 国药集团一致药业股份有限公司（以下简称"公司"）第十届监事 会2025年第二次临时会议于2025年4月18日以电话和电子邮件方式发 出通知和文件材料，于2025年4月24日在深圳以现场结合视频会议方 式召开，监事会主席文德镛先生主持会议。会议应参会监事3人，实 际参会监事3人。会议召开程序符合《公司法》《公司章程》的有关 规定。监事列席了第十届董事会2025年第五次临时会议。 特此公告。 国药集团一致药业股份有限公司监事会 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 25 日 二、监事会会议审核情况 本次会议审核通过了《公司 2025 年第一季度报告》。 表决结果：同意 3 票，反对 0 票、弃权 0 票。 一、监事会会议召开情况 ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-26 国药集团一致药业股份有限公司 第十届董事会2025年第五次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果：7 票同意，0 票反对，0 票弃权。（具体内容详见当 日公告及巨潮资讯网） 本议案经董事会风险内控与审计委员会 2025年第二次会议审议 通过。 2. 审议通过了《关于制定<市值管理制度>的议案》 为加强公司市值管理工作，维护全体股东尤其是中小投资者的合 法权益，提升公司投资价值，公司依据国资委《关于改进和加强中央 企业控股上市公司市值管理工作的若干意见》以及证监会《上市公司 监管指引第 10 号——市值管理》的要求，制定了《市值管理制度》。 表决结果：7 票同意，0 票反对，0 票弃权。（具体内容详见当 日公告及巨潮资讯网） 3. 审议通过了《关于国大药房（日照）有限公司清算注销的议案》 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"）第十届董事 会2025年第五次临时会议于2025年4月18日以电话和电子邮件 ...

第一章 总则 第一条 为加强国药集团一致药业股份有限公司（以下简称"公司"）市值管 理，进一步加强与规范公司的市值管理行为，维护公司、投资者及其他利益相关 者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司监管指引第 10 号——市值管理》《深圳证券交易所股票上市规则》等法 律法规、规范性文件及《国药集团一致药业股份有限公司章程》（以下简称"《公 司章程》"）的规定，结合公司实际情况，制定本制度。 国药集团一致药业股份有限公司 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升投 资者回报能力和水平而实施的战略管理行为。 市值管理制度 第三条 市值管理的基本原则包括： （一）合规性原则：在严格遵守相关法律法规、规范性文件、自律监管规则 以及《公司章程》等内部规章制度的前提下开展市值管理工作。 （二）系统性原则：按照系统思维、整体推进的原则，改善影响公司市值增 长的各大关键要素。 （三）科学性原则：市值管理依其规律科学而为，不能违背其内在逻辑。公 司将科学研判影响公司投资价值的关键性因素，以提升公司质量为基础开展市值 管理工作。 （四）常态性原则：公司将及时关注资本市场 ...

Group 1 - The core point of the article is that China National Pharmaceutical Group Corporation (国药一致) reported a decline in both revenue and net profit for the first quarter of 2025, indicating potential challenges in its financial performance [1] Group 2 - The company's revenue for the first quarter of 2025 was 18.294 billion yuan, representing a year-on-year decrease of 4.17% [1] - The net profit for the same period was 328 million yuan, which reflects a year-on-year decline of 15.63% [1]

Financial Performance - In Q1 2025, the company reported revenue of CNY 18.29 billion, a decrease of 4.17% compared to CNY 19.09 billion in the same period last year[5]. - Net profit attributable to shareholders was CNY 327.99 million, down 15.63% from CNY 388.77 million year-on-year, with basic earnings per share decreasing by 15.71% to CNY 0.59[5]. - The distribution segment generated revenue of CNY 13.59 billion, a decline of 2.61%, while net profit was CNY 23.10 million, down 3.75% year-on-year[5]. - The retail segment, represented by Guoda Pharmacy, achieved revenue of CNY 4.98 billion, a decrease of 7.49%, with net profit plummeting 94.28% to CNY 0.04 million[5]. - The net profit for the current period is CNY 347,677,306.80, a decrease of 22.1% compared to CNY 446,123,063.02 in the previous period[21]. - The total profit for the current period is CNY 438,326,864.61, down from CNY 550,249,302.13, reflecting a decline of 20.3%[21]. - The operating profit for the current period is CNY 439,138,215.70, compared to CNY 544,001,136.48 in the previous period, indicating a decrease of 19.3%[21]. - The company reported a decrease in sales revenue from CNY 16,287,280,704.30 to CNY 15,787,668,453.64, a decline of 3.1%[22]. Cash Flow and Assets - The company experienced a significant increase in cash flow from operating activities, reporting a net cash outflow of CNY 1.82 billion, compared to a net outflow of CNY 634.15 million in the previous year, marking a 186.57% decline[5]. - Cash flow from operating activities decreased by 118,312.42 million yuan, a decline of 186.57% due to increased payable notes and delayed receivables[12]. - Net cash flow from investment activities decreased by 2,047.98 million yuan, a drop of 82.44%, primarily due to reduced returns from investment projects[12]. - Cash flow from financing activities decreased by 33,042.73 million yuan, a reduction of 33.32%, mainly attributed to timing differences in factoring business[12]. - Total cash and cash equivalents decreased by 121,806.13 million yuan, a decline of 214.79%, influenced by increased payable notes and decreased sales scale[12]. - Cash and cash equivalents at the end of the period amount to CNY 5,338,493,281.93, slightly up from CNY 5,268,204,527.14 in the previous period[23]. - Current assets totaled ¥40,139,860,703.30, up from ¥37,576,395,698.77, representing an increase of 6.77%[18]. - Non-current assets decreased slightly to ¥9,883,181,465.79 from ¥9,979,464,716.45, a decline of 0.97%[18]. - Total liabilities increased to ¥28,921,099,065.70 from ¥26,800,461,097.40, marking an increase of 7.87%[19]. - Accounts receivable increased to ¥23,588,402,403.91 from ¥19,376,751,928.72, reflecting an increase of 21.43%[18]. - Inventory increased to ¥8,021,262,862.14 from ¥7,406,159,009.11, an increase of 8.31%[18]. - Long-term equity investments rose to ¥3,045,046,646.19 from ¥2,944,833,760.49, an increase of 3.41%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,428[14]. - The largest shareholder, China National Pharmaceutical Group Corporation, holds 56.06% of shares, totaling 311,999,988 shares[15]. - The second-largest shareholder, National Social Security Fund 413 Portfolio, holds 1.36% of shares, totaling 7,560,013 shares[15]. Strategic Focus - The company is focusing on enhancing operational management in the distribution business and improving efficiency in the retail segment through dynamic management of loss-making stores[6]. - The company aims to strengthen its core business and develop a standardized management system to foster sustainable growth amidst a challenging market environment[6]. Other Financial Metrics - Basic and diluted earnings per share are both CNY 0.59, down from CNY 0.70 in the previous period[21]. - The total cash inflow from financing activities is CNY 661,184,385.13, compared to CNY 991,611,668.12 in the previous period, a decrease of 33.3%[23]. - The company incurred credit impairment losses of CNY -63,856,766.00, compared to CNY -40,849,138.51 in the previous period, indicating an increase in losses[21]. - The company has not yet audited the first quarter report for 2025[25].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事全体人员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 国药集团一致药业股份有限公司（以下简称"公司"）于2025年4月8日发布公司2024年年度报告，并将于 4月25日发布公司2025年第一季度报告，为便于投资者了解公司经营情况及未来发展规划，将举办2024 年度暨2025年第一季度业绩说明会，现将有关事项公告如下： 一、说明会召开的时间、地点和方式 会议召开方式：现场交流 二、参加人员 董事长、独立董事、总经理、财务总监、董事会秘书将出席此次业绩说明会。 三、投资者参加方式 1、预约报名。请拟参与本次业绩说明会的投资者，于2025年4月28日（星期一）12:00前通过网址 https://eseb.cn/1nueUcIbYWs或使用微信扫描下方小程序码进行预约登记，以便做好相关安排。 ■ 预约报名时需提交的资料： 公司将对上述文件进行查验并存档，以备监管机构查阅。 预约报名成功的投资者，将收到参会短信通知。届时可于2025年4月29日下午会前15分钟到达，凭参会 短信通知，履行现场登记手续后进入会场，参与本次业绩说明 ...